Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers
Recognition of erectile dysfunction (ED) as an early sign of systemic cardiovascular disease offers an opportunity for prevention. Cardiac risk assessment may deserve measurement of Apolipoprotein B/Apolipoprotein A-1 ratio. An elevated ApoB/ApoA-1 ratio is a risk factor for future coronary artery d...
Gespeichert in:
| Veröffentlicht in: | Progrès en urologie (Paris) 2008-12, Vol.18 (13), p.1087-1091 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1091 |
|---|---|
| container_issue | 13 |
| container_start_page | 1087 |
| container_title | Progrès en urologie (Paris) |
| container_volume | 18 |
| creator | Roumeguère, T Zouaoui Boudjeltia, K Hauzeur, C Ramal, A Schulman, C Vanhaeverbeek, M Ducobu, J Wespes, E |
| description | Recognition of erectile dysfunction (ED) as an early sign of systemic cardiovascular disease offers an opportunity for prevention. Cardiac risk assessment may deserve measurement of Apolipoprotein B/Apolipoprotein A-1 ratio. An elevated ApoB/ApoA-1 ratio is a risk factor for future coronary artery disease. ApoA-1 production, which is recognized as a cardioprotective lipid fraction, is down regulated by NFkappaB activation in vitro. Because inhibition of phosphodiesterases (PDEs) 5, 6 and 9 negatively attenuates NFkappaB translocation/activation, tadalafil, a selective PDE 5 inhibitor used for treatment of ED could present some interesting pleiotropic effects. The objective of this open study is to test the hypothesis that tadalafil treatment could decrease serum ApoB/ApoA-1 ratio.
Ten healthy men without any complain of ED or known cardiovascular risk factors were administered tadalafil 10mg intake on alternate days for 4 weeks. Lipid profile with total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, ApoA-1 and ApoB, was assessed at baseline (T0), after 2weeks (T1), at the end of the treatment period (T2) and after 2weeks of wash-out follow-up (T3).
ApoB/ApoA-1 ratio was significantly decreased during treatment (mean+/-SEM, T0: 0.80+/-0.11, T1: 0.64+/-0.06, T2: 0.65+/-0.06; p |
| doi_str_mv | 10.1016/j.purol.2008.09.057 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69847791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69847791</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-57828761786bee5bc61b613a71c14be97c278c1db8b84cdc0c20a68a87e383a33</originalsourceid><addsrcrecordid>eNo1kM1OwzAQhH0AUSg8ARLyiVtSb9PaDhdUyq9UCQ5wrjbOVjU4cbCdSn0CXptIlMvMYT6NNMPYJYgcBMjJZ971wbt8KoTORZmLuTpipwBSZkpoNWJnMX4KIYe4PGEjKMUMNMhT9nNPJhBG4ovO300GWWTAAybrObY1Nxhq63cYTe8w8GDjF7dNF_yOGmrTDUeesEaHG-t458j6FHxnDafNhky65W-BnG1si2HPY-rrPfct3xK6tN3znXd9m4hCPGfHG3SRLg4-Zh-PD-_L52z1-vSyXKyyDooyZXOlp1pJUFpWRPPKSKgkFKjAwKyiUpmp0gbqSld6ZmojzFSg1KgVFbrAohiz67_eYcJ3TzGtGxsNOYct-T6uZalnSpUwgFcHsK8aqtddsM2wYf1_XfELo4Nyyw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69847791</pqid></control><display><type>article</type><title>Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Roumeguère, T ; Zouaoui Boudjeltia, K ; Hauzeur, C ; Ramal, A ; Schulman, C ; Vanhaeverbeek, M ; Ducobu, J ; Wespes, E</creator><creatorcontrib>Roumeguère, T ; Zouaoui Boudjeltia, K ; Hauzeur, C ; Ramal, A ; Schulman, C ; Vanhaeverbeek, M ; Ducobu, J ; Wespes, E</creatorcontrib><description>Recognition of erectile dysfunction (ED) as an early sign of systemic cardiovascular disease offers an opportunity for prevention. Cardiac risk assessment may deserve measurement of Apolipoprotein B/Apolipoprotein A-1 ratio. An elevated ApoB/ApoA-1 ratio is a risk factor for future coronary artery disease. ApoA-1 production, which is recognized as a cardioprotective lipid fraction, is down regulated by NFkappaB activation in vitro. Because inhibition of phosphodiesterases (PDEs) 5, 6 and 9 negatively attenuates NFkappaB translocation/activation, tadalafil, a selective PDE 5 inhibitor used for treatment of ED could present some interesting pleiotropic effects. The objective of this open study is to test the hypothesis that tadalafil treatment could decrease serum ApoB/ApoA-1 ratio.
Ten healthy men without any complain of ED or known cardiovascular risk factors were administered tadalafil 10mg intake on alternate days for 4 weeks. Lipid profile with total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, ApoA-1 and ApoB, was assessed at baseline (T0), after 2weeks (T1), at the end of the treatment period (T2) and after 2weeks of wash-out follow-up (T3).
ApoB/ApoA-1 ratio was significantly decreased during treatment (mean+/-SEM, T0: 0.80+/-0.11, T1: 0.64+/-0.06, T2: 0.65+/-0.06; p<0.05) and remained lower after wash-out (T3: 0.67+/-0.05; p=0.08). Serum ApoA-1 (mg/dl) increased but not significantly during the treatment period (15.2+/-8.8, 16.5+/-7.9, 16.9+/-6, 15.3+/-7, p=0.26) and ApoB (mg/dl) significantly decreased (11.7+/-10.8, 10.3+/-8.4, 10.6+/-9.9, 10.2+/-8.6, p=0.03). HDL and LDL cholesterol were unchanged.
This preliminary study showed the interest of PDE 5 inhibitors to decrease the cardiac risk factor ApoB/ApoA-1 ratio. Randomised controlled studies with longer follow-up are needed to confirm those results.</description><identifier>ISSN: 1166-7087</identifier><identifier>DOI: 10.1016/j.purol.2008.09.057</identifier><identifier>PMID: 19041816</identifier><language>fre</language><publisher>France</publisher><subject>Adult ; Apolipoprotein A-I - blood ; Apolipoproteins B - blood ; Carbolines - therapeutic use ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - prevention & control ; Humans ; Male ; Middle Aged ; Phosphodiesterase Inhibitors - therapeutic use ; Risk Factors ; Tadalafil</subject><ispartof>Progrès en urologie (Paris), 2008-12, Vol.18 (13), p.1087-1091</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19041816$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roumeguère, T</creatorcontrib><creatorcontrib>Zouaoui Boudjeltia, K</creatorcontrib><creatorcontrib>Hauzeur, C</creatorcontrib><creatorcontrib>Ramal, A</creatorcontrib><creatorcontrib>Schulman, C</creatorcontrib><creatorcontrib>Vanhaeverbeek, M</creatorcontrib><creatorcontrib>Ducobu, J</creatorcontrib><creatorcontrib>Wespes, E</creatorcontrib><title>Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers</title><title>Progrès en urologie (Paris)</title><addtitle>Prog Urol</addtitle><description>Recognition of erectile dysfunction (ED) as an early sign of systemic cardiovascular disease offers an opportunity for prevention. Cardiac risk assessment may deserve measurement of Apolipoprotein B/Apolipoprotein A-1 ratio. An elevated ApoB/ApoA-1 ratio is a risk factor for future coronary artery disease. ApoA-1 production, which is recognized as a cardioprotective lipid fraction, is down regulated by NFkappaB activation in vitro. Because inhibition of phosphodiesterases (PDEs) 5, 6 and 9 negatively attenuates NFkappaB translocation/activation, tadalafil, a selective PDE 5 inhibitor used for treatment of ED could present some interesting pleiotropic effects. The objective of this open study is to test the hypothesis that tadalafil treatment could decrease serum ApoB/ApoA-1 ratio.
Ten healthy men without any complain of ED or known cardiovascular risk factors were administered tadalafil 10mg intake on alternate days for 4 weeks. Lipid profile with total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, ApoA-1 and ApoB, was assessed at baseline (T0), after 2weeks (T1), at the end of the treatment period (T2) and after 2weeks of wash-out follow-up (T3).
ApoB/ApoA-1 ratio was significantly decreased during treatment (mean+/-SEM, T0: 0.80+/-0.11, T1: 0.64+/-0.06, T2: 0.65+/-0.06; p<0.05) and remained lower after wash-out (T3: 0.67+/-0.05; p=0.08). Serum ApoA-1 (mg/dl) increased but not significantly during the treatment period (15.2+/-8.8, 16.5+/-7.9, 16.9+/-6, 15.3+/-7, p=0.26) and ApoB (mg/dl) significantly decreased (11.7+/-10.8, 10.3+/-8.4, 10.6+/-9.9, 10.2+/-8.6, p=0.03). HDL and LDL cholesterol were unchanged.
This preliminary study showed the interest of PDE 5 inhibitors to decrease the cardiac risk factor ApoB/ApoA-1 ratio. Randomised controlled studies with longer follow-up are needed to confirm those results.</description><subject>Adult</subject><subject>Apolipoprotein A-I - blood</subject><subject>Apolipoproteins B - blood</subject><subject>Carbolines - therapeutic use</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Phosphodiesterase Inhibitors - therapeutic use</subject><subject>Risk Factors</subject><subject>Tadalafil</subject><issn>1166-7087</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kM1OwzAQhH0AUSg8ARLyiVtSb9PaDhdUyq9UCQ5wrjbOVjU4cbCdSn0CXptIlMvMYT6NNMPYJYgcBMjJZ971wbt8KoTORZmLuTpipwBSZkpoNWJnMX4KIYe4PGEjKMUMNMhT9nNPJhBG4ovO300GWWTAAybrObY1Nxhq63cYTe8w8GDjF7dNF_yOGmrTDUeesEaHG-t458j6FHxnDafNhky65W-BnG1si2HPY-rrPfct3xK6tN3znXd9m4hCPGfHG3SRLg4-Zh-PD-_L52z1-vSyXKyyDooyZXOlp1pJUFpWRPPKSKgkFKjAwKyiUpmp0gbqSld6ZmojzFSg1KgVFbrAohiz67_eYcJ3TzGtGxsNOYct-T6uZalnSpUwgFcHsK8aqtddsM2wYf1_XfELo4Nyyw</recordid><startdate>200812</startdate><enddate>200812</enddate><creator>Roumeguère, T</creator><creator>Zouaoui Boudjeltia, K</creator><creator>Hauzeur, C</creator><creator>Ramal, A</creator><creator>Schulman, C</creator><creator>Vanhaeverbeek, M</creator><creator>Ducobu, J</creator><creator>Wespes, E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200812</creationdate><title>Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers</title><author>Roumeguère, T ; Zouaoui Boudjeltia, K ; Hauzeur, C ; Ramal, A ; Schulman, C ; Vanhaeverbeek, M ; Ducobu, J ; Wespes, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-57828761786bee5bc61b613a71c14be97c278c1db8b84cdc0c20a68a87e383a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Apolipoprotein A-I - blood</topic><topic>Apolipoproteins B - blood</topic><topic>Carbolines - therapeutic use</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Phosphodiesterase Inhibitors - therapeutic use</topic><topic>Risk Factors</topic><topic>Tadalafil</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roumeguère, T</creatorcontrib><creatorcontrib>Zouaoui Boudjeltia, K</creatorcontrib><creatorcontrib>Hauzeur, C</creatorcontrib><creatorcontrib>Ramal, A</creatorcontrib><creatorcontrib>Schulman, C</creatorcontrib><creatorcontrib>Vanhaeverbeek, M</creatorcontrib><creatorcontrib>Ducobu, J</creatorcontrib><creatorcontrib>Wespes, E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Progrès en urologie (Paris)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roumeguère, T</au><au>Zouaoui Boudjeltia, K</au><au>Hauzeur, C</au><au>Ramal, A</au><au>Schulman, C</au><au>Vanhaeverbeek, M</au><au>Ducobu, J</au><au>Wespes, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers</atitle><jtitle>Progrès en urologie (Paris)</jtitle><addtitle>Prog Urol</addtitle><date>2008-12</date><risdate>2008</risdate><volume>18</volume><issue>13</issue><spage>1087</spage><epage>1091</epage><pages>1087-1091</pages><issn>1166-7087</issn><abstract>Recognition of erectile dysfunction (ED) as an early sign of systemic cardiovascular disease offers an opportunity for prevention. Cardiac risk assessment may deserve measurement of Apolipoprotein B/Apolipoprotein A-1 ratio. An elevated ApoB/ApoA-1 ratio is a risk factor for future coronary artery disease. ApoA-1 production, which is recognized as a cardioprotective lipid fraction, is down regulated by NFkappaB activation in vitro. Because inhibition of phosphodiesterases (PDEs) 5, 6 and 9 negatively attenuates NFkappaB translocation/activation, tadalafil, a selective PDE 5 inhibitor used for treatment of ED could present some interesting pleiotropic effects. The objective of this open study is to test the hypothesis that tadalafil treatment could decrease serum ApoB/ApoA-1 ratio.
Ten healthy men without any complain of ED or known cardiovascular risk factors were administered tadalafil 10mg intake on alternate days for 4 weeks. Lipid profile with total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, ApoA-1 and ApoB, was assessed at baseline (T0), after 2weeks (T1), at the end of the treatment period (T2) and after 2weeks of wash-out follow-up (T3).
ApoB/ApoA-1 ratio was significantly decreased during treatment (mean+/-SEM, T0: 0.80+/-0.11, T1: 0.64+/-0.06, T2: 0.65+/-0.06; p<0.05) and remained lower after wash-out (T3: 0.67+/-0.05; p=0.08). Serum ApoA-1 (mg/dl) increased but not significantly during the treatment period (15.2+/-8.8, 16.5+/-7.9, 16.9+/-6, 15.3+/-7, p=0.26) and ApoB (mg/dl) significantly decreased (11.7+/-10.8, 10.3+/-8.4, 10.6+/-9.9, 10.2+/-8.6, p=0.03). HDL and LDL cholesterol were unchanged.
This preliminary study showed the interest of PDE 5 inhibitors to decrease the cardiac risk factor ApoB/ApoA-1 ratio. Randomised controlled studies with longer follow-up are needed to confirm those results.</abstract><cop>France</cop><pmid>19041816</pmid><doi>10.1016/j.purol.2008.09.057</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1166-7087 |
| ispartof | Progrès en urologie (Paris), 2008-12, Vol.18 (13), p.1087-1091 |
| issn | 1166-7087 |
| language | fre |
| recordid | cdi_proquest_miscellaneous_69847791 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Apolipoprotein A-I - blood Apolipoproteins B - blood Carbolines - therapeutic use Cardiovascular Diseases - blood Cardiovascular Diseases - prevention & control Humans Male Middle Aged Phosphodiesterase Inhibitors - therapeutic use Risk Factors Tadalafil |
| title | Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T10%3A08%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Decrease%20ApoB/ApoA-1%20ratio%20and%20cardiovascular%20risk%20improvement:%20a%20tadalafil%20pleiotropic%20effect?%20Preliminary%20study%20on%20healthy%20volunteers&rft.jtitle=Progre%CC%80s%20en%20urologie%20(Paris)&rft.au=Roumegu%C3%A8re,%20T&rft.date=2008-12&rft.volume=18&rft.issue=13&rft.spage=1087&rft.epage=1091&rft.pages=1087-1091&rft.issn=1166-7087&rft_id=info:doi/10.1016/j.purol.2008.09.057&rft_dat=%3Cproquest_pubme%3E69847791%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69847791&rft_id=info:pmid/19041816&rfr_iscdi=true |